MYOPEP

Some of the main dysfunctions related to being overweight are obesity, dyslipidemia and hyperglycemia.

Obesity can be due to insulin resistance, whereby the muscles, liver, and fat cells resist the uptake of glucose from the blood, resulting in high blood sugar. Myopep aids to counter insulin sensitivity by activating both PPARϒ and PPARα, inhibiting the breaking-down and formation of new fat cells, and stopping the absorption of lipid in the intestine.

The insulin-like effect of this formula increases glucose uptake in adipocytes (fat cells) and stimulate glucose utilization, regulating insulin receptor genes in the skeletal muscles. As the insulin receptor genes are upregulated, this will initiate the reduction of glucose absorption.

This may ultimately assist in managing weight-gain linked to insulin resistance, as it promotes better glucose breakdown to suppress high blood sugar levels after a meal. Obesity and resistance towards insulin accelerate the progression of developing dyslipidemia. The lipid lowering effect of Myopep inhibits the activity of cholesteryl ester transfer protein (CETP). CETP inhibition plays a crucial role in reversing transport of cholesterol as a therapy to potentially raise good HDL cholesterol (High density lipoprotein). The increment of HDL cholesterol (good) will automatically reduce the amount of LDL cholesterol (bad) in the body. The anti oxidative property of Cinnamon cassia reduces the oxidative stress damage in the liver, facilitating optimum cholesterol metabolism. The blocking of HMG CoA reductase inhibits the synthesis of cholesterol.